Publications by authors named "Stanley Cohan"

Claim this Profile
S
Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study.
Robert J Fox, Stanley Cohan, Yang Mao-Draayer, Bianca Weinstock-Guttman, Linda-Ali Cruz

Mult Scler· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.
Ralph Hb Benedict, Ludwig Kappos, Aaron Miller, Hans-Peter Hartung, James Overell, Stanley Cohan

Mult Scler Relat Disord· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Sergey A Kornilov, Nathan D Price, Richard Gelinas, Juan Acosta, Mary E Brunkow, Stanley Cohan

J Neurol Sci· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis.
Kyle Smoot, Tiffany Gervasi-Follmar, Horia Marginean, Chiayi Chen, Stanley Cohan

Mult Scler Relat Disord· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorder.
Anisha M Patel, Alex Exuzides, Irina Yermilov, Hannah Dalglish, Sarah N Gibbs, Stanley Cohan

J Neurol Sci· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
Mitzi J Williams, Lilyana Amezcua, Stanley L Cohan, Jeffrey A Cohen, Silvia R Delgado

Neurology· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study.
Ralph H B Benedict, Pamela Vo, Nicholas Adlard, Olwyn Grennan, Ashley Enstone, Stanley L Cohan

Clinicoecon Outcomes Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM.
Mitzi J Williams, Lilyana Amezcua, Angel Chinea, Stanley Cohan, Annette Okai

Neurol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Le H Hua, Amit Bar-Or, Stanley L Cohan, Fred D Lublin, Patricia K Coyle

Mult Scler Relat Disord· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
Kyle Smoot, Horia Marginean, Tiffany Gervasi-Follmar, Chiayi Chen, Pavle Repovic, Stanley Cohan

Mult Scler· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
Stanley L Cohan, Ralph H B Benedict, Bruce A C Cree, John DeLuca, Le H Hua

CNS Drugs· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing Care and Outcomes for African American Patients With Multiple Sclerosis.
Annette F Okai, Annette M Howard, Mitzi J Williams, Justine D Brink, Chiayi Chen, Stanley L Cohan

Neurology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study.
Helmut Butzkueven, Paul S Giacomini, Stanley Cohan, Tjalf Ziemssen, Daniel Sienkiewicz

Brain Sci· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.
Stanley Cohan, Tiffany Gervasi-Follmar, Aneesh Kamath, Vineetha Kamath, Chiayi Chen

Mult Scler J Exp Transl Clin· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
Stanley Cohan, Jinender Kumar, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic

CNS Drugs· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis.
Stanley Cohan, Tom Tencer, Stella Arndorfer, Xuelian Zhu, Marko Zivkovic

Mult Scler Relat Disord· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).
Stanley L Cohan, Barry A Hendin, Anthony T Reder, Kyle Smoot, Robin Avila

CNS Drugs· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study.
Kyle Smoot, Chiayi Chen, Tamela Stuchiner, Lindsay Lucas, Lois Grote, Stanley Cohan

BMJ Neurol Open· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND.
Pavle Repovic, Derrick Robertson, Kiren Kresa-Reahl, Stanley L Cohan, Ray Su

Neurol Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination.
Ludwig Kappos, Stanley Cohan, Douglas L Arnold, Randy R Robinson, Joan Holman

Ther Adv Neurol Disord· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM.
Mitzi J Williams, Lilyana Amezcua, Annette Okai, Darin T Okuda, Stanley Cohan

Neurol Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
Tamela Stuchiner, Lindsay Lucas, Elizabeth Baraban, Kateri J Spinelli, Chiayi Chen, Stanley Cohan

BMC Neurol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study.
Abhishek Pratap, Daniel Grant, Ashok Vegesna, Meghasyam Tummalacherla, Stanley Cohan

JMIR Mhealth Uhealth· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sphingosine-1-Phosphate: Its Pharmacological Regulation and the Treatment of Multiple Sclerosis: A Review Article.
Stanley Cohan, Elisabeth Lucassen, Kyle Smoot, Justine Brink, Chiayi Chen

Biomedicines· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis.
Stanley L Cohan, Elisabeth B Lucassen, Meghan C Romba, Stefanie N Linch

Biomedicines· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis